Correlation Between Unicycive Therapeutics and 50249AAJ2

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and 50249AAJ2 at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and 50249AAJ2 into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Unicycive Therapeutics and LYB INTERNATIONAL FINANCE, you can compare the effects of market volatilities on Unicycive Therapeutics and 50249AAJ2 and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of 50249AAJ2. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and 50249AAJ2.

Diversification Opportunities for Unicycive Therapeutics and 50249AAJ2

-0.42
  Correlation Coefficient

Very good diversification

The 3 months correlation between Unicycive and 50249AAJ2 is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and LYB INTERNATIONAL FINANCE in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on LYB INTERNATIONAL FINANCE and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with 50249AAJ2. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of LYB INTERNATIONAL FINANCE has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and 50249AAJ2 go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and 50249AAJ2

Given the investment horizon of 90 days Unicycive Therapeutics is expected to under-perform the 50249AAJ2. In addition to that, Unicycive Therapeutics is 6.26 times more volatile than LYB INTERNATIONAL FINANCE. It trades about -0.01 of its total potential returns per unit of risk. LYB INTERNATIONAL FINANCE is currently generating about 0.05 per unit of volatility. If you would invest  6,767  in LYB INTERNATIONAL FINANCE on September 24, 2024 and sell it today you would earn a total of  602.00  from holding LYB INTERNATIONAL FINANCE or generate 8.9% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy96.39%
ValuesDaily Returns

Unicycive Therapeutics  vs.  LYB INTERNATIONAL FINANCE

 Performance 
       Timeline  
Unicycive Therapeutics 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
LYB INTERNATIONAL FINANCE 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days LYB INTERNATIONAL FINANCE has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, 50249AAJ2 is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Unicycive Therapeutics and 50249AAJ2 Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Unicycive Therapeutics and 50249AAJ2

The main advantage of trading using opposite Unicycive Therapeutics and 50249AAJ2 positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, 50249AAJ2 can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 50249AAJ2 will offset losses from the drop in 50249AAJ2's long position.
The idea behind Unicycive Therapeutics and LYB INTERNATIONAL FINANCE pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets